Premium
In vitro and in vivo effects of diethylstilbestrol and estramustine phosphate (estracyt®) on the mitogen responsiveness of human peripheral blood lymphocytes
Author(s) -
Haukaas Svein,
Høisaeter Per Åge,
Kalland Terje
Publication year - 1982
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.2990030410
Subject(s) - diethylstilbestrol , in vivo , estramustine , phytohaemagglutinin , in vitro , endocrinology , medicine , lymphocyte , mitogen activated protein kinase , prostate , cancer , immunology , biology , estrogen , prostate disease , biochemistry , microbiology and biotechnology
The responsiveness to diethylstilbestrol (DES) and estramustinephosphate (EMP) of human peripheral blood lymphocytes to T‐cell mitogens has been investigated in vitro and in vivo. EMP demonstrated potent inhibiton of both Con A‐and PHA‐induced lymphocyte proliferation in vitro, while it had no detectable effects when given to patients with cancer of the prostate. DES reduced the response to Con A in vitro, but had only marginal effects on PHA‐induced mitogen response. In contrast, the response to Con A was unaltered, while the response to PHA was significantly diminished after DES therapy in patients with prostatic cancer. This effect, however, was only seen when high doses of DES not included in conventional regimen were given. The proliferative response to T‐cell mitogens in patients with prostatic cancer was not affected by serum source in the assay, indicating the absence of humoral factors able to inhibit mitogen response in these patients.